One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 1.5 million shares of Allogene Therapeutics Inc. (NASDAQ: ALLO) on Tuesday. The price of this ETF was down more than 1% in Tuesday’s session, and it is down a fair amount in the past year.
It was the ARK Genomic Revolution ETF (NYSEARCA: ARKG) that added 1,581,099 shares of Allogene. At Tuesday’s closing price, this would have valued this purchase at roughly $22.6 million. This is only a small fraction of the total holdings. The ETF is down roughly 37% in the past year.
Check out all of ARK Invest’s buys for Tuesday:
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.